Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Universal community carrier screening for cystic fibrosis?

Nature Genetics volume 3, pages 195–201 (1993)Cite this article

Abstract

Approximately 5% of the Caucasian North European and North American populations are carriers of the gene defect causing cystic fibrosis (CF). Since the CF gene was isolated in 1989 and the common mutations identified, there has been debate as to whether community–wide screening for CF carriers should be offered. Pilot studies and new discussions are leading to a consensus that screening is now possible and will not lead to undue anxiety, but there is still no agreement as to cost, or how it will be used by those screening positive.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. U.S. Congress Office of Technology Assessment Cystic Fibrosis and DNA Tests: Implications of Carrier Screening (OTA-BA532, U. S. Government Printing Office, Washington, D.C., 1992).

  2. World Health Organization Report of a Joint WHO/ICF(M)A Task Force on Cystic Fibrosis WHO/HDP/ICF(M)A/TF/90. 4, Hereditary Diseases Programme (World Health Organization, Geneva, 1991).

  3. Watson, E.K., Mayall, E.S., Lamb, J., Chapple, J. & Williamson, R. Psychological and social consequences of community carrier screening programme for cystic fibrosis. Lancet 340, 217–220 (1992).

    Article  CAS  Google Scholar 

  4. Mennie, M.A. et al. Prenatal screening for cystic fibrosis. Lancet 340, 214–216 (1992).

    Article  CAS  Google Scholar 

  5. Witt, D.R. et al. Cystic fibrosis carrier screening in a prenatal population. Am. J. hum. Genet. 51, A16 (Supplement) (1992).

    Google Scholar 

  6. Wainwright, B.J. et al. Localisation of cystic fibrosis locus to human chromosome 7cen-q2. Nature 318, 384–385 (1985).

    Article  CAS  Google Scholar 

  7. Tsui, L.-C. et al. Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science 230, 1054–1057 (1985).

    Article  CAS  Google Scholar 

  8. White, R. et al. A closely linked genetic marker for cystic fibrosis. Nature 318, 382–384 (1985).

    Article  CAS  Google Scholar 

  9. Farrall, M. First-trimester prenatal diagnosis of cystic fibrosis with linked DNA probes. Lancet ii, 1402–1404 (1986).

    Article  Google Scholar 

  10. Feldman, G.L., Williamson, R., Beaudet, A.L. & O'Brien, W.E. Prenatal diagnosis of cystic fibrosis by DNA amplification for detection of KM-19 polymorphism. Lancet ii, 102–103 (1988).

    Article  Google Scholar 

  11. Kerem, B. et al. Identification of the cystic fibrosis gene: genetic analysis. Science 245, 1073–1080 (1989).

    Article  CAS  Google Scholar 

  12. Rommens, J.M. et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245, 1059–1065 (1989).

    Article  CAS  Google Scholar 

  13. Riordan, J.R. et al. Identification of the cystic fibrosis gene: cloning and characterisation of complementary DNA. Science 245, 1066–1073 (1989).

    Article  CAS  Google Scholar 

  14. Modell, B. & Kuliev, A.M. Services for thalassaemia as a model for cost benefit analysis of genetic services. J. Inher. metab. Dis. 14, 640–651 (1991).

    Article  CAS  Google Scholar 

  15. American Society of Human Genetics Board of Directors (1992) Statement on cystic fibrosis carrier screening. Am. J. hum. Genet. 51, 1443–1444 (1992).

  16. Wexler, N.S. The Tiresias complex: Huntington's disease as a paradigm of testing for late-onset disorders. FASEB J. 6, 2820–2825 (1992).

    Article  CAS  Google Scholar 

  17. Ferec, C. et al. Detection of over 98% cystic fibrosis mutations in a Celtic population. Nature Genet. 1, 188–192 (1992).

    Article  CAS  Google Scholar 

  18. Johnansen, H.K., Nir, M., Hoiby, N., Koch, C. & Schwartz, M. Severity of cystic fibrosis in patients homozygous and heterozygous for the DF508 mutation. Lancet 337, 631–634 (1991).

    Article  Google Scholar 

  19. Rozen, R. et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. Am. J. med. Genet. 42, 360–364 (1992).

    Article  CAS  Google Scholar 

  20. Lucotte, G. & Hazout, S. A NW-SE Decreasing gradient of the ΔF508 frequencies in Europe. Newslett. EC Cystic Fibrosis Consort. 1, (1990).

  21. Tsui, L.-C. The spectrum of cystic fibrosis mutations. Trends Genet. 8, 392–398 (1992).

    Article  CAS  Google Scholar 

  22. Scriver, C.R. & Fujiwara, T.M. Cystic fibrosis genotypes and views on screening are both heterogeneous and population related. Am. J. hum. Genet. 51, 943–950 (1992).

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Reilly, P. ASHG statement on genetics and privacy: testimony to United States Congress. Am. J. hum. Genet. 50, 640–642 (1992).

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Wilfond, B.S. & Fost, N. The cystic fibrosis gene: medical and social implications for heterozygote detection. J. Am. Med. Assn. 263, 2777–2783 (1990).

    Article  CAS  Google Scholar 

  25. Billings, P.R. et al. Discrimination as a consequence of genetic testing. Am. J. Hum. Genet. 50, 476–482 (1992).

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Watson, E.K., Williamson, R. & Chapple, J. Attitudes to carrier screening for cystic fibrosis: a survey of health care professionals, relatives of sufferers and other members of the public. Br. J. Gen. Prac. 41, 237–240 (1991).

    CAS  Google Scholar 

  27. Borgo, G., Fabiano, T., Perobelli, S. & Mastella, G. Effect of introducing prenatal diagnosis on the reproductive behavior of families at risk for cystic fibrosis: a cohort study. Prenatal Diag. 12, 821–830 (1992).

    Article  CAS  Google Scholar 

  28. Modell, B., Ward, R.H. & Fairweather, D.V. The effect of introducing antenatal diagnosis on reproductive behavior of families at risk for Thalassaemia Major. Br. med. J. 280, 1347–1350 (1980).

    Article  CAS  Google Scholar 

  29. Williamson, R. et al. Community attitudes to cystic fibrosis carrier testing in England: A pilot study. Prenatal Diag. 9, 727–734 (1989).

    Article  CAS  Google Scholar 

  30. Watson, E.K. et al. Screening for carriers of cystic fibrosis through primary health care services. Br. med. J. 303, 504–507 (1991).

    Article  CAS  Google Scholar 

  31. Lench, N., Stanier, P. & Williamson, R. Simple non-invasive method to obtain DNA for gene analysis. Lancet i, 1356–1358 (1988).

    Article  Google Scholar 

  32. Lyonnet, S. et al. Guthrie cards for detection of point mutations in phenylketonuria. Lancet ii, 507 (1988).

    Article  Google Scholar 

  33. Williams, C., Weber, L., Williamson, R. & Hjelm, M. Guthrie spots for DNA-based carrier testing in cystic fibrosis. Lancet ii, 693 (1988).

    Article  Google Scholar 

  34. Higuchi, R., von Beroldingen, C.H., Sensabaugh, G.F. & Erlich, H.A. DNA typing from single hairs. Nature 332, 543–545 (1988).

    Article  CAS  Google Scholar 

  35. Berlin, Y.A. & Kazazian, H.H. Rapid preparation of genomic DNA from dried blood and saliva spots for polymerase chain reaction. Hum. Mut. 1, 260–261 (1992).

    Article  CAS  Google Scholar 

  36. Kaplan, F. et al. Cystic fibrosis carrier detection by DNA test: a population study: carrierfrequencies and attitudes toward atest with imperfect sensitivity. Am. J. hum. Genet. 51, A268 (Supplement) (1992).

    Google Scholar 

  37. Harris, H.J., Scotcher, D., Craufurd, D., Wallace, A. & Harris, R. Cystic fibrosis carrier screening at first diagnosis of pregnancy in general practice. Lancet 339, 1539 (1992).

    Article  CAS  Google Scholar 

  38. Wald, N.J. Couple screening for cystic fibrosis. Lancet 338, 1318–1319 (1991).

    Article  CAS  Google Scholar 

  39. Super, M., Schwarz, M.J. & Malone, G. Screening for cystic fibrosis carriers. Lancet 340, 490–491 (1992).

    Article  CAS  Google Scholar 

  40. Newton, C.R. et al. Detection of DF508 deletion by amplification refractory mutation system (ARMS). Lancet 335, 1217–1219 (1990).

    Article  CAS  Google Scholar 

  41. Gille, C., Grade, K. & Coutelle, C. A pooling strategy for heterozygote screening of the DF508 cystic fibrosis mutation. Hum. Genet. 86, 289–291 (1991).

    Article  CAS  Google Scholar 

  42. Cutting, G.R. Two steps closer to gene therapy for cystic fibrosis. Nature Genet. 2, 4–5 (1992).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry and Molecular Genetics, St. Mary's Hospital Medical School, Imperial College, London, W2 1PG, UK

    Robert Williamson

Authors
  1. Robert Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Williamson, R. Universal community carrier screening for cystic fibrosis?. Nat Genet 3, 195–201 (1993). https://doi.org/10.1038/ng0393-195

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng0393-195

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing